CARs are engineered proteins that redirect immune cells to recognize specific targets. For Tregs, this means designing CARs that bind only to unique markers on transplanted tissues, ensuring ...

Immerse yourself in the latest advancements in CAR-Tregs, IL-2, and novel mutein therapies through our two comprehensive tracks of content. As the ultimate hub for all things Treg, this summit is ...

These efforts include lab-modified Tregs (CAR-Tregs and T-cell receptor Tregs) as well as the design of therapeutic molecules ...

SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell ...

Quell Therapeutics Ltd (“Quell” or “the Company”), and eXmoor pharma (“eXmoor”), announce a strategic partnership for the manufacture of multiple autologous engineered CAR-Treg cell therapies in Quell ...

SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell ...